Physician profile
Elsa L Pineda-Flores
NPI 1528605961
$24,148.16
in general payments reported to CMS, 2019-2025
73 companies · $4,754 in 2025
The $4,754 reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,632 · 2022: $4,198 · 2023: $5,552 · 2024: $6,012 · 2025: $4,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Long Term Medical Supply Or Device Loan: $1,597 · Education: $928 · Consulting Fee: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,916.25 |
| Long Term Medical Supply Or Device Loan | $1,596.68 |
| Education | $927.57 |
| Consulting Fee | $877.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,540.98 | 2021-2025 | |
| Janssen Biotech, INC. | $1,333.66 | 2022-2025 | Erleada, Tecvayli, Akeega |
| Emd Serono, INC. | $1,210.27 | 2021-2025 | Bavencio |
| Pfizer INC. | $1,080.79 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,057.85 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $911.28 | 2021-2025 | Reblozyl, Onureg, Opdualag |
| Incyte Corporation | $847.94 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Lilly USA, LLC | $801.88 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $772.06 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $748.51 | 2021-2025 | Iclusig, Fruzaqla, Alunbrig |
| Astellas Pharma US INC | $679.63 | 2021-2025 | Xtandi, Xospata, Padcev |
| Karyopharm Therapeutics INC. | $666.32 | 2021-2025 | Xpovio |
| Abbvie INC. | $622.80 | 2022-2025 | |
| Daiichi Sankyo INC. | $575.16 | 2021-2025 | Enhertu, Vanflyta, Datroway |
| Amgen INC. | $545.84 | 2021-2023 | Lumakras, Vectibix, Nplate |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $477.63 | 2021-2025 | Calquence, Lynparza |
| Seagen INC. | $472.10 | 2021-2025 | Tivdak, Adcetris, Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $460.20 | 2021-2023 | Imbruvica, Epkinly |
| Exelixis INC. | $455.28 | 2021-2025 | Cabometyx |
| Genzyme Corporation | $452.80 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $405.08 | 2022-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $400.82 | 2021-2025 | Jemperli, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $372.17 | 2021-2025 | Opdivo, Opdualag |
| Sobi, INC | $316.09 | 2022-2025 | |
| Eisai INC. | $298.72 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.11 | 2021-2025 | Gilotrif |
| Gilead Sciences, INC. | $279.73 | 2021-2025 | Trodelvy |
| Pharmaessentia USA Corporation | $273.61 | 2022-2025 | Besremi |
| Array Biopharma INC | $228.39 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Deciphera Pharmaceuticals INC. | $225.65 | 2022-2025 | Qinlock, Tgct |
| Ipsen Biopharmaceuticals, INC | $202.38 | 2021-2024 | Onivyde, Somatuline Depot |
| Stemline Therapeutics INC. | $196.53 | 2023-2025 | Orserdu |
| Beigene USA, INC. | $182.09 | 2023-2024 | Brukinsa |
| Taiho Oncology, INC. | $177.31 | 2021-2025 | |
| Genentech USA, INC. | $175.05 | 2023-2025 | Venclexta, Tecentriq, Polivy |
| Genmab U.S., INC. | $161.41 | 2024-2025 | Epkinly |
| Blueprint Medicines Corporation | $146.80 | 2021-2024 | Ayvakit |
| Vantive US Healthcare LLC | $120.01 | 2025 | Renal - Pd |
| Progenics Pharmaceuticals, INC. | $115.78 | 2023-2025 | Pylarify |
| Kite Pharma, INC. | $108.45 | 2021-2023 | |
| Global Blood Therapeutics, INC. | $106.08 | 2021-2022 | |
| Morphosys, US INC. | $105.82 | 2021-2023 | Monjuvi |
| Tolmar Pharmaceuticals, INC. | $104.22 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $103.78 | 2025 | Clonoseq |
| Sun Pharmaceutical Industries INC. | $88.44 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $83.00 | 2022 | |
| Immunogen, INC. | $81.18 | 2023 | Elahere |
| Jazz Pharmaceuticals INC. | $80.47 | 2021-2025 | |
| Kyowa Kirin, INC. | $73.15 | 2024 | Poteligeo |
| Beone Medicines USA, INC. | $68.20 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $67.48 | 2023-2024 | Libtayo |
| Novocure INC. | $63.97 | 2025 | Optune Lua (Novottf-200t) |
| Geron Corporation | $63.35 | 2024-2025 | Rytelo |
| Syndax Pharmaceuticals, INC. | $59.82 | 2025 | |
| Acrotech Biopharma INC. | $56.63 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $55.76 | 2025 | Danziten |
| Puma Biotechnology, INC. | $52.17 | 2025 | |
| Novo Nordisk INC | $41.57 | 2023 | Esperoct |
| Rigel Pharmaceuticals, INC. | $41.00 | 2021-2022 | |
| Chiesi USA, INC. | $36.30 | 2023-2025 | Ferriprox |
| Emmaus Medical, INC. | $33.87 | 2024 | Endari |
| Agios Pharmaceuticals, INC. | $33.04 | 2025 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $32.74 | 2025 | |
| Myriad Genetic Laboratories, INC. | $30.23 | 2024 | Myrisk |
| Adc Therapeutics America, INC. | $28.43 | 2025 | |
| Organon LLC | $27.64 | 2022 | |
| Foundation Medicine, INC. | $27.45 | 2023 | Foundationone Liquid Cdx |
| Apellis Pharmaceuticals, INC. | $24.31 | 2023 | Empaveli |
| Tolmar, INC. | $23.35 | 2023 | |
| Ge Healthcare | $21.67 | 2022 | |
| Servier Pharmaceuticals LLC | $19.20 | 2022 | |
| Coherus Oncology, INC. | $17.28 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $16.40 | 2023 | Sancuso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elsa Pineda-Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.